



Join Keystone Symposia
for the 2016 conference on:

Purinergic Signaling

January 24–28, 2016

Fairmont Hotel Vancouver | Vancouver, British Columbia | Canada

Scientific Organizers:

Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

Joint with the conference on

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies

This meeting will integrate rapidly emerging information about the regulation of purine release from cells (in vesicles and via channels and transporters); signaling via membrane-associated receptors (adenosine, P2X and P2Y) and extracellular metabolism (via CD73, CD39 and other ecto-enzymes); and new structural information that is facilitating drug discovery. These processes mediate tissue responses to a continual flux of signaling purines in the extracellular space that profoundly influence inflammatory diseases, tissue repair and immune function. A focus on the effects of hypoxia, metabolic stress and cytokines will fill gaps in our current knowledge of how these factors influence signaling during the evolution of acute and chronic inflammation. An understanding of how purinergic signals are dynamically regulated is needed to identify improved therapies, e.g., for cancer immunotherapy, since tumors exploit these pathways to avoid immune surveillance. The meeting will focus on the paradigm-shifting realization of dynamic purinergic regulation in the setting of disease progression.

Session Topics:

- Purine Release
 - Purine Metabolism
 - Adenosine and P2Y Structure and Medicinal Chemistry
 - Drugs Targeting Adenosine Receptors
 - Cancer Immunotherapy I & II
 - Purinergic Signaling in the CNS
 - P2 Receptors
- plus four afternoon workshops*



Submitting an abstract is a great way of participating in the conference through poster presentation and possible selection for a short talk.

Scholarship & Discounted Abstract Deadline: Sep 29, 2015

Abstract Deadline: Oct 29, 2015

Discounted Registration Deadline: Nov 24, 2015

For additional details, visit www.keystonesymposia.org/16J5.

KEYSTONE SYMPOSIA™
on Molecular and Cellular Biology

Accelerating Life Science Discovery

www.keystonesymposia.org/meetings | 1.800.253.0685 | 1.970.262.1230

a 501(c)(3) nonprofit educational organization

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Purinergic Signaling (J5)

Scientific Organizers: Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

Sponsored by Bayer HealthCare Pharmaceuticals

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)

Scientific Organizers: Barbara Seliger, Jerome Galon and Francesco M. Marincola

January 24-28, 2016 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Sponsored by BioLegend, Inc., Caladrius Biosciences, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Abstract & Scholarship Deadline: September 29, 2015 / Abstract Deadline: October 29, 2015 / Discounted Registration Deadline: November 24, 2015

SUNDAY, JANUARY 24

Arrival and Registration

MONDAY, JANUARY 25

Welcome, Video Greeting from Dr. Geoffrey Burnstock and Keynote Address (J5)

Simon C. Robson, Beth Israel Deaconess Medical Center, USA
Purinergic Signaling and Conditioning of Inflammatory Responses in Clinical Disease.

Welcome and Keynote Address (J6)

Robert D. Schreiber, Washington University School of Medicine, USA
Personalizing Cancer Immunotherapy

Purine Release (J5)

Gerhard Dahl, University of Miami, USA
ATP Release through Pannexon Channels.

Francesco Di Virgilio, University of Ferrara, Italy
ATP: A Novel Constituent of the Tumor Microenvironment affecting Tumor Growth and Metastatic Spreading

Kodi S. Ravichandran, University of Virginia, USA
Apoptotic Purine Signaling

Short Talk(s) Chosen from Abstracts

Tumor Microenvironment and Effector Cells (J6)

Thomas Blankenstein, Max Delbrück Center for Molecular Medicine, Germany
Adoptive T Cell Therapy

Sandra Demaria, Weill Cornell Medical College, USA
Harnessing Radiotherapy to Overcome Tumor Resistance to Immunotherapy

Fathia Mami-Chouaib, Institut Gustave Roussy, France
Paradoxical role of TGF-beta in Promoting CTL Effector Functions within Epithelial Tumor Microenvironment by Triggering CD103 Integrin Expression and Signaling

Short Talk(s) Chosen from Abstracts

Workshop 1 (J5)

Short Talks Chosen from Abstracts

Purine Metabolism (J5)

Norbert Sträter, University of Leipzig, Germany
Structure and Function of CD39 and CD73 in Purinergic Signalling

Elizabeth Hartland, University of Melbourne, Australia
Microbial NTPDases and their Role During Infection

Ridong Chen, APT Therapeutics, Inc., USA
APT102, an Optimized Human Apyrase, Attenuates Arterial Thrombosis without Increasing Bleeding Risk

Short Talk Chosen from Abstracts

Immune Signature and Biomarkers (J6)

Jerome Galon, INSERM U872, Cordeliers Research Center, France
Importance of the Immune Infiltration and Cancer Classification

Francesco M. Marincola, Sidra Medical and Research Center, Qatar
A Panoramic View of Tumor Rejection Induced by Immune Therapy

Ton N. Schumacher, Netherlands Cancer Institute, Netherlands
T cell Recognition and Tumor Resistance in Human Cancer

Short Talk Chosen from Abstracts

Poster Session 1

TUESDAY, JANUARY 26

Adenosine and P2Y Structure and Medicinal Chemistry (J5)

Mark J. Yeager, University of Virginia, USA
Structural Biology of Adenosine Receptor G-Protein Complexes

Ruben Abagyan, University of California, San Diego, USA
Modeling and Structure Based Discovery of Allosteric Modulators

Kenneth A. Jacobson, NIDDK, National Institutes of Health, USA
Structure-Based Design of P2Y Receptor Ligands

Christa E. Müller, Universität Bonn, Germany
Medicinal Chemistry of Purinergic Signalling

Short Talk(s) Chosen from Abstracts

System Biology and Dysregulation in Cancer (J6)

Speakers to be Announced

Carlo M. Croce, Ohio State University, USA
Causes and Consequences of microRNA Dysregulation in Cancer

Ofer Mandelboim, Hebrew University, Israel
Importance of Bacteria in Modulating NK Cell Response against Tumors

Short Talk(s) Chosen from Abstracts

Poster Session 2

Workshop 2 (J5)

Short Talks Chosen from Abstracts

Drugs Targeting Adenosine Receptors (J5)

Tomyuki Kanda, Kyowa Hakko Kirin Co., Ltd., Japan
Adenosine A2A Receptor as Therapeutic Target for Parkinson's and Neurodegeneration

Joel Linden, La Jolla Institute for Allergy and Immunology, USA
Inhibition of Sterile Inflammation by Adenosine

Pnina Fishman, Can-Fite BioPharma Ltd., Israel
Utilizing the A3 Adenosine Receptor as a Target to Combat Cancer: From Lab to Labeling

Short Talk Chosen from Abstracts

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Purinergic Signaling (J5)

Scientific Organizers: Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

Sponsored by Bayer HealthCare Pharmaceuticals

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)

Scientific Organizers: Barbara Seliger, Jerome Galon and Francesco M. Marincola

January 24-28, 2016 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Sponsored by BioLegend, Inc., Caladrius Biosciences, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Abstract & Scholarship Deadline: September 29, 2015 / Abstract Deadline: October 29, 2015 / Discounted Registration Deadline: November 24, 2015

Cancer Immunotherapy: Adoptive T Cell Transfer and Cell Therapy (J6)

Nicholas P. Restifo, NCI, National Institutes of Health, USA
Adoptive T Cell Transfer

Adrian Bot, Kite Pharma, Inc., USA
Optimizing the Translation of Genetically Programmed T Cells to Safe and Potent Therapies

Gerold Schuler, University Hospital of Erlangen, Germany
Monocyte-derived Dendritic Cells as Vaccines: Beyond Simple Induction of T Cells

Ronald Levy, Stanford University, USA
Targeting the Immune System while Targeting the Cancer Customized vs. Off-the-Shelf Therapies

Short Talk Chosen from Abstracts

WEDNESDAY, JANUARY 27

Cancer Immunotherapy I (J5)

Gennady G. Yegutkin, University of Turku, Finland
Cellular Purine Homeostasis as a Complex and Coordinated Network Controlling Tumor Invasion and Migration

John Stagg, Institut du cancer de Montréal, Canada
CD73-mediated Adenosine Signaling in Human Cancers

Michail Sitkovsky, Northeastern University, USA
Conceptually Novel "Anti-Hypoxia-A2A-Adenosinergic" Checkpoint Inhibitors to Improve Immunotherapies and Chemotherapies of Cancer

Caglar Cekic, Bilkent University, Turkey
Adenosine regulation of myeloid cells in solid tumors

Short Talk(s) Chosen from Abstracts

Immune Suppression and the Role of Paracrine Factors in Modulating Immune Suppression (J6)

Barbara Seliger, Martin Luther University, Germany
Escape of Tumors from Immune Cell Recognition by Modulating MHC Class I Antigen Processing Components

Edgardo D. Carosella, Hôpital Saint Louis, France
Role of HLA-G in Human Tumors

Thorald van Hall, Leiden University Medical Center, Netherlands
HLA-E in cancer: from immune escape to therapeutic target?

Short Talk(s) Chosen from Abstracts

Workshop 3 (J5)

Short Talks Chosen from Abstracts

Cancer Immunotherapy II (J5)

Mark J. Smyth, Peter MacCallum Cancer Centre/QIMR Berghofer Medical Research Institute, Australia
Strategies for Combination Cancer Immunotherapies that Target Adenosine

Phillip K. Darcy, Peter MacCallum Cancer Centre, Australia
Enhancing Adoptive Cellular Therapy by Targeting Tumor-Induced Immunosuppression

Kris F. Sachsenmeier, MedImmune LLC, USA
MEDI9447: Targeting CD73 in the Tumor Microenvironment.

Short Talk Chosen from Abstracts

Novel Immunotherapeutic Approaches and Antibody Therapies (J6)

James P. Allison, University of Texas MD Anderson Cancer Center, USA

Tumor Targeting using Checkpoint Antibodies

Gregory Lawrence Beatty, University of Pennsylvania, USA
Activating Innate and Adaptive Immunity by CD40 Agonists

Nils Lonberg, Bristol-Myers Squibb, USA
Immune Checkpoints and Combination Therapy

Short Talk Chosen from Abstracts

Poster Session 3

THURSDAY, JANUARY 28

Purinergic Signaling in the CNS (J5)

Kazuhide Inoue, Kyushu University, Japan
Purinergic Regulation of Microglia in Neuropathic Pain

Maria P. Abbracchio, University of Milan, Italy
Purinergic Regulation of Oligodendrocyte Precursor Cells and Myelination

Masahiro Mishina, Nippon Medical School, Japan
Brain Imaging of Adenosine Receptors

Francisco J. Quintana, Harvard Medical School, USA
Talk Title to be Announced

Short Talk(s) Chosen from Abstracts

Immune Escape Mechanisms by Immune Suppressive Cells/Factors (J6)

Thomas Gajewski, University of Chicago, USA
Molecular Mechanisms of the T Cell-Inflamed Tumor Microenvironment: Implications for Immunotherapy

Rolf Kiessling, Karolinska Institute, Sweden
Targeting CSF-1R Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma Growth Through Modulating Suppressive Myeloid Cells

David H. Munn, Georgia Regents University, USA
IDO, PTEN and Activated Tregs in the Tumor Microenvironment

Speaker to be Announced

Role of Metabolic Changes on the Immune Response

Short Talk(s) Chosen from Abstracts

Workshop 4 (J5)

KEYSTONE SYMPOSIA

on Molecular and Cellular Biology

Purinergic Signaling (J5)

Scientific Organizers: Joel Linden, Mark J. Smyth, Simon C. Robson and Kenneth A. Jacobson

Sponsored by Bayer HealthCare Pharmaceuticals

Cancer Immunotherapy: Immunity and Immunosuppression Meet Targeted Therapies (J6)

Scientific Organizers: Barbara Seliger, Jerome Galon and Francesco M. Marincola

January 24-28, 2016 • Fairmont Hotel Vancouver • Vancouver, British Columbia, Canada

Sponsored by BioLegend, Inc., Caladrius Biosciences, Inc., Genentech, Inc., Genmab A/S, ImmunoGen, Inc., Incyte Corporation, Infinity Pharmaceuticals, Inc., Mersana Therapeutics, MorphoSys AG, Pfizer Inc., Regeneron Pharmaceuticals, Inc., Sanofi US, Shire Human Genetic Therapies and Thermo Fisher Scientific Inc.

Abstract & Scholarship Deadline: September 29, 2015 / Abstract Deadline: October 29, 2015 / Discounted Registration Deadline: November 24, 2015

Short Talks Chosen from Abstracts

P2 Receptors (J5)

Marco Cattaneo, Università degli Studi di Milano, Italy

Talk Title to be Announced

Rosaria Volpini, Università degli Studi di Camerino, Italy

P2 Receptor Ligands: Overview and Updates

Mufeng Li, NINDS, National Institutes of Health, USA

Structure and Gating Mechanisms of ATP Activated P2X Receptor Channels

Targeted Therapies and Combination Therapies (J6)

Boris Minev, University of California, San Diego and Genelux, USA

The Role of Immunity in Oncolytic Therapy

Hyam I. Levitsky, Juno Therapeutics, Inc., USA

Combination Agonists, Checkpoint Inhibitors, and Vaccines: Gas Pedals, Breaks, and Steering Wheels.

Michele Maio, University Hospital of Siena, Italy

Sequential Therapy of Checkpoint Inhibitors with Targeted Therapies

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (J5)

Meeting Wrap-Up: Outcomes and Future Directions (Organizers) (J6)

FRIDAY, JANUARY 29

Departure